Relay Therapeutics stock analysis: up nearly ninefold on zovegalisib hopes, but with about $10M of revenue and steady losses the model says Sell.
@2026 – All Right Reserved.
Tag:
Sell
-
-
Aerospace & DefenseUS Stocks
Kratos Defense Is 67% Below Its Two-Year High, but a 253 P/E and Cash Burn Keep the Model at Sell
Kratos Defense stock analysis: 30.5% revenue growth, but a 253 P/E, cash burn and dilution keep the model’s signal at Sell after a 67% fall.
-
SemiconductorsUS Stocks
MaxLinear Jumps 15% to $105.93 on AI Optical Demand – but at 17 Times Revenue With No Trailing Profit, the Model Still Signals Sell
MaxLinear stock analysis: revenue up 55% on AI optical demand, but 17.03 times revenue and no trailing profit keep the model at Sell.
-
SoftwareUS Stocks
CoreWeave Is Burning $9 Billion a Year to Chase AI Demand – Can the Balance Sheet Keep Up?
CoreWeave stock analysis: 112% revenue growth collides with a -$9.1B free cash flow and 10x leverage. Model signal: Sell.
-
BiotechnologyUS Stocks
IDEAYA Biosciences: Trading Near a Two-Year High While the Model Flags a Sell
IDEAYA Biosciences, Inc. stock analysis: shares sit near a two-year high while a -36.4% gross margin and 25/100 quality score drive a Sell signal.
-
IREN Limited stock analysis: a 68.9% gross margin offset by $4.2B of cash burn, revenue down 26.7%, and a Sell signal from our scoring model.
-
Hut 8 Corp. stock analysis: HUT has run roughly 10x off its two-year low, but a 22/100 Quality score and heavy cash burn make it a model Sell.
Newer Posts